D. Markwardt

Patients with cirrhosis and SBP: Increase in multidrug‐resistant organisms and complications

J. Mayerle, R. Hornung, A. Gerbes, 2019, European journal of clinical investigation.

Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study

J. Mayerle, E. D. De Toni, A. Geier, 2022, Journal of Cancer Research and Clinical Oncology.

Plasma cystatin C is a predictor of renal dysfunction, acute‐on‐chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis

F. Nevens, R. Moreau, L. Holdt, 2017, Hepatology.

Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study

A. Gerbes, H. Wedemeyer, K. Weissenborn, 2020, European journal of gastroenterology & hepatology.

Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis.

J. Mayerle, R. Hornung, A. Gerbes, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV

H. Blum, E. Khatamzas, S. Krebs, 2022, Medical Oncology.

Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study

J. Mayerle, E. D. De Toni, A. Geier, 2022, Journal of Cancer Research and Clinical Oncology.

P476 SHORT-TERM (28-DAY) CLINICAL COURSE AND TRANSPLANT-FREE MORTALITY IN ACUTE ON CHRONIC LIVER FAILURE (ACLF); EVIDENCE FOR REVERSIBILITY OF ACLF (A STUDY FROM THE CANONIC DATABASE)

R. Moreau, R. Jalan, J. Trebicka, 2014 .